LCTX

Business Context and Reporting Period

Company: BioTime, Inc. (Note: Input metadata referenced "Lineage Cell Therapeutics," but the filing text identifies the registrant as BioTime, Inc.)
Reporting Period: Fiscal year ended December 31, 2000.
Business Stage: Development stage company engaged in the research and development of synthetic blood plasma volume expanders, blood replacement solutions for hypothermic surgery, and organ preservation solutions.
Key Product: Hextend®, a physiologically balanced blood plasma volume expander approved for use in major surgery. It is sold in the U.S. and Canada under an exclusive license to Abbott Laboratories and globally (excluding U.S., Canada, Japan) under a license to Horus B.V. (Akzo Nobel).

Key Financial Metrics

Revenue Composition (2000): Entirely derived from royalties on product sales ($52,492). No license fee revenue was recognized in 2000, compared to $1,037,500 in 1999.
Expenses: Research and Development (R&D) expenses were $3,362,841 (down from $4.9M in 1999). General and Administrative (G&A) expenses were $1,779,931 (down from $1.9M in 1999).

Material Changes vs. Prior Period

• Revenue Decline: Total revenue dropped significantly from $1.04M in 1999 to $52k in 2000. This is primarily due to the absence of license fee revenue in 2000, as the $1.04M recognized in 1999 related to deferred fees from the Abbott agreement received in prior years.
• Improved Loss Position: Net loss decreased by approximately $555,000 year-over-year, driven by reduced R&D and G&A expenses.
• Cash Burn: Cash and cash equivalents decreased by approximately $4.0M (from $5.3M to $1.3M), reflecting continued operating losses and a net cash outflow from operating activities of $4.86M.
• Product Sales Growth: Despite the drop in recognized revenue, management notes that quarterly sales of Hextend increased approximately 600% from Q4 1999 to Q4 2000. Royalties on Q4 2000 sales ($32,695) were not recognized until Q1 2001 due to accounting policies regarding sales reports.

Outlook, Risks, and Contingencies

Liquidity and Capital Needs: The Company requires additional capital to continue operations. As of December 31, 2000, cash on hand ($1.3M) and a new $1.0M revolving line of credit (entered March 2001 with Alfred D. Kingsley) are expected to fund operations for approximately 12 months. The Company anticipates receiving a $4.0M initial license fee from Horus B.V. (Akzo Nobel) upon confirmation of manufacturing arrangements, with up to $5.5M in additional milestone fees possible.

Guidance and Strategy: Management expects R&D expenses to increase as new clinical studies for PentaLyte and HetaCool commence. The Company is seeking regulatory approval for Hextend in the European Union and Canada. Future profitability depends on the successful marketing of Hextend by Abbott and Horus, and the development of new products.

Risk Factors:

• Development Stage: The Company has incurred cumulative losses of over $27M since inception and has no assurance it will achieve profitability.
• Regulatory Approval: Future products (PentaLyte, HetaCool) require FDA and foreign regulatory approval, which is costly, time-consuming, and uncertain.
• Competition: Hextend competes with albumin, generic hetastarch solutions, and crystalloids. Price competition is intense, particularly from generic products.
• Dependence on Licensees: Revenue generation relies heavily on Abbott and Horus to successfully manufacture, market, and sell products.
• Supply Chain: The Company relies on third parties for the supply of hydroxyethyl starch, a key ingredient.

Investor Verification Checklist

• License Fee Timing: Verify the status of the $4.0M initial license fee from Horus B.V. and the conditions required for its release (manufacturing/supply arrangements).
• Cash Runway: Confirm the utilization of the $1.0M line of credit and the timeline for any required equity or debt financing to fund clinical trials for PentaLyte and HetaCool.
• Sales Recognition Lag: Monitor Q1 2001 financials for the recognition of Q4 2000 royalties ($32,695) to validate the sales growth trend cited by management.
• Regulatory Milestones: Track the status of Hextend regulatory approvals in the European Union and Canada, as these are prerequisites for Horus to begin sales.
• Patent Protection: Review the status of patents in key markets, as royalty rates under the Horus agreement are contingent on patent protection in the country of sale.